Drugs / M032
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07076498 | Apr 2026 → Dec 2029 expected | glioma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT02062827 | Nov 2013 → Sep 2022 overdue | anaplastic astrocytoma, glioblastoma | University of Alabama at Birmingham | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05084430 | Feb 2022 → Mar 2027 expected | anaplastic astrocytoma, gliosarcoma | University of Alabama at Birmingham | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M032 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05084430 ↗ |
| Known as | NSC 733972 | “A Phase 1 Study of M032 (NSC 733972), a Genetically Engineered HSV-1 Expressing IL-12, in Patients With Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma,...” NCT02062827 ↗2“IL-12-expressing HSV-1 NSC 733972 (M032) administered intratumorally via stereotactic intratumoral injection” NCT07076498 ↗ “Study of Pembrolizumab and M032 (NSC 733972)” NCT05084430 ↗ |
| Route | Other | “infused through catheters into region(s) of tumor” NCT02062827 ↗ |